gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MTVAHealthcarePharmaceuticals

MetaVia Inc. Common Stock (MTVA)

$1.34+6.35%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$1.17▼ 89.36% in range
Nov 3, 2025Low $0.97 · High $11.88Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

MetaVia closed at $1.34 on Nov 4, up 6.35%, 88.7% below its 52-week closing high. Volume of 148.2K shares was 2.13× its 20-day average (well above normal).

Split-adjusted performance: -9.5% over one month, -4.3% over six months, -87.8% over one year.

Short interest was 98.7K shares at the Oct 15 settlement, down 15.9% from the prior report (2.9% of float, 1.4 days to cover).

Market cap$8.8M6.6M shares
Revenue · quarter$0.00—
Diluted EPS$-0.90—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range0.97 – 11.88−88.7% from high
Volume148.2K2.13× 20-day avg
Volatility · 60d65.1%Annualised
Short % of float2.9%1.5 days to cover
Net cash$9.8MCash $12.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +17.5%1M −9.5%3M −7.6%6M −4.3%YTD −84.1%1Y −87.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum69
Revenue growth—
Net margin—
Value (low P/E)—
Size14

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short98.7K−15.9% vs prior
Days to cover1.5Settled Oct 15
% of float2.9%
Short vol. 10d42.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MTVAMetaVia$1.34+6.35%−4.3%———$8.8M
ACTUActuate Therapeutics$0.3699+5.69%−87.6%———$8.9MCompare
LTRNLantern Pharma$0.5866−2.61%−72.6%———$8.8MCompare
GTBPGT Biopharma$4.84−8.16%−51.9%———$8.7MCompare
TOVXTheriva Biologics$0.1900+4.40%−50.3%———$8.7MCompare
MBRXMoleculin Biotech$8.46+1.93%−82.9%———$8.6MCompare
LEXXLexaria Bioscience$4.07+0.99%−59.8%−100.0%——$8.6MCompare
CURXCuranex Pharmaceuticals$5.80−6.30%−17.7%———$9.1MCompare
CALCCalciMedica$1.35−8.50%−56.8%———$9.2MCompare

News about MetaVia

All news →

No recent articles focused on MetaVia. 2 articles mention it in passing.

Quick answers

What does MetaVia do?
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
What is MTVA's market cap?
$8.83M, based on the Nov 4 close of $1.34.
Does MetaVia pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MTVA is sold short?
98.7K shares, 2.9% of float, as of Oct 15, 2026.
What sector is MTVA in?
Healthcare, in the Pharmaceuticals industry.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

HQ: Cambridge, MA8 employeesListed Aug 4, 2016metaviatx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology